Revenue: As of FY2025 Q2, the actual value is USD 250 K.EPS: As of FY2025 Q2, the actual value is USD -0.39, beating the estimate of USD -0.56.<h3>Segment Revenue</h3><ul><li>Collaboration Agreements: Revenue from collaboration agreements was $250,000 for the three months ended June 30, 2025, compared to $1,073,000 for the same period in 2024. For the six months ended June 30, 2025, revenue was $250,000 compared to $53,477,000 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Research and Development Expenses: Research and development expenses were $14,283,000 for the three months ended June 30, 2025, compared to $30,075,000 for the same period in 2024. For the six months ended June 30, 2025, expenses were $34,553,000 compared to $63,045,000 for the same period in 2024.</li><li>General and Administrative Expenses: General and administrative expenses were $6,029,000 for the three months ended June 30, 2025, compared to $8,317,000 for the same period in 2024. For the six months ended June 30, 2025, expenses were $13,681,000 compared to $16,935,000 for the same period in 2024.</li><li>Restructuring Expenses: Restructuring expenses were $3,384,000 for the three months ended June 30, 2025, and $6,649,000 for the six months ended June 30, 2025. There were no restructuring expenses for the same periods in 2024.</li><li>Net Loss: Net loss was $16,744,000 for the three months ended June 30, 2025, compared to $34,774,000 for the same period in 2024. For the six months ended June 30, 2025, net loss was $46,787,000 compared to $21,612,000 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was $45,475,000 for the six months ended June 30, 2025, compared to $18,582,000 for the same period in 2024.</li><li>Investing Cash Flow: Net cash provided by investing activities was $28,206,000 for the six months ended June 30, 2025, compared to net cash used in investing activities of $13,198,000 for the same period in 2024.</li><li>Financing Cash Flow: Net cash provided by financing activities was $79,000 for the six months ended June 30, 2025, compared to $375,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Gain on Sale of Technology and Other Assets: The company recognized a gain of $5,666,000 on the sale of technology and other assets for the three and six months ended June 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focusing on the continued advancement of its Phase 1 clinical programs, RP-3467 and RP-1664. Expected milestones include topline safety, tolerability, and early efficacy data from the POLAR trial in Q4-2025 and initial topline safety, tolerability, and early efficacy data from the LIONS trial in Q4-2025.</li><li>Non-Core Business: The company has out-licensed its early-stage discovery platforms to DCx Biotherapeutics Corporation and entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib. These transactions are expected to provide near-term payments and potential future milestone payments and royalties.</li><li>Priority: The company is actively exploring strategic alternatives, partnerships, and sale opportunities across its portfolio to maximize shareholder value.</li></ul>

Repare Therapeutics | 10-Q: FY2025 Q2 Revenue: USD 250 K